Asahi Kasei Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asahi Kasei Corporation
Emergex is preparing to begin a Phase I study of its T-cell priming vaccine, RedHill BioPharma has completed enrolment in a Phase II/III study of upamostat, and Australia is assessing Moderna’s Spikevax for use in 6-11 year olds.
The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.
Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?
The Israeli biotech announced disappointing Phase II/III data for opaganib while expanding its Phase II/III RHB-107 study. Pharming unveiled promising data from a company-sponsored study, but an imbalance in an investigator-led study confounded results, while CalciMedica built on the case for its drug as a treatment for COVID-19 pneumonia.
- Medical Devices
- Other Names / Subsidiaries
- Advanced Circulatory Systems, Inc.
- Artisan Pharmaceuticals
- Asahi Kasei Holdings US, Inc.
- Asahi Kasei Pharma America Corp. (AKP America)
- Cardiac Science Corporation
- Golden Hour Data Systems, Inc.
- Kyma Medical Technologies, Ltd.
- Mobilize RRS LLC.
- TherOx, Inc.
- Veloxis Pharmaceuticals Inc.
- ZOLL Medical Corporation